Diabetes and prediabetes in patients with hepatitis B residing in North America

Mandana Khalili, Manuel Lombardero, Raymond T. Chung, Norah A. Terrault, Marc G. Ghany, W. Ray Kim, Daryl Lau, Mauricio Lisker‐Melman, Arun Sanyal, Anna S. Lok, for the HBRN – 8 August 2015 – Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV‐infected multiethnic cohort.

Diabetes and prediabetes in patients with hepatitis B residing in North America

Mandana Khalili, Manuel Lombardero, Raymond T. Chung, Norah A. Terrault, Marc G. Ghany, W. Ray Kim, Daryl Lau, Mauricio Lisker‐Melman, Arun Sanyal, Anna S. Lok, for the HBRN – 8 August 2015 – Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV‐infected multiethnic cohort.

High‐throughput T‐cell receptor sequencing across chronic liver diseases reveals distinct disease‐associated repertoires

Evaggelia Liaskou, Eva Kristine Klemsdal Henriksen, Kristian Holm, Fatemeh Kaveh, David Hamm, Janine Fear, Marte K. Viken, Johannes Roksund Hov, Espen Melum, Harlan Robins, Johanna Olweus, Tom H. Karlsen, Gideon M. Hirschfield – 7 August 2015 – Hepatic T‐cell infiltrates and a strong genetic human leukocyte antigen association represent characteristic features of various immune‐mediated liver diseases. Conceptually the presence of disease‐associated antigens is predicted to be reflected in T‐cell receptor (TCR) repertoires.

Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade

Dong‐Xian Guan, Jie Shi, Yang Zhang, Jiang‐Sha Zhao, Ling‐Yun Long, Tian‐Wei Chen, Er‐Bin Zhang, Yuan‐Yuan Feng, Wen‐Dai Bao, Yue‐Zhen Deng, Lin Qiu, Xue‐Li Zhang, H. Phillip Koeffler, Shu‐qun Cheng, Jing‐Jing Li, Dong Xie – 7 August 2015 – Sorafenib is a specific adenosine triphosphate–competitive RAF inhibitor used as a first‐line treatment of advanced hepatocellular carcinoma (HCC). However, the responses are variable, reflecting heterogeneity of the disease, while the resistance mechanism remains poorly understood.

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity

Alla Kachko, Sharon E. Frey, Lev Sirota, Ranjit Ray, Frances Wells, Iryna Zubkova, Pei Zhang, Marian E. Major – 6 August 2015 – Hepatitis C virus (HCV) neutralization occurring at the E2 region 412‐426 (EP‐I) could be enhanced when antibodies directed specifically to the E2 region 434‐446 (EP‐II) were removed from serum samples of persistently infected patients and vaccinated chimpanzees, a phenomenon of so‐called antibody interference. Here, we show that this type of interference can be observed in individuals after immunization with recombinant E1E2 proteins.

A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance

Hui Wang, Souhayla El Maadidi, Janett Fischer, Elena Grabski, Sabine Dickhöfer, Sascha Klimosch, Sinead M. Flannery, Angela Filomena, Olaf‐Oliver Wolz, Nicole Schneiderhan‐Marra, Markus W. Löffler, Manfred Wiese, Tica Pichulik, Beat Müllhaupt, David Semela, Jean‐François Dufour, Pierre‐Yves Bochud, Andrew G. Bowie, Ulrich Kalinke, Thomas Berg, Alexander N.R.

Subscribe to